These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
106 related items for PubMed ID: 14571352
1. Acute effects of cholecystokinin tetrapeptide on brain stem auditory evoked potentials in healthy volunteers. Gunnarsson T, Mahoney C, Shlik J, Bradwejn J, Knott V. Pharmacopsychiatry; 2003 Sep; 36(5):181-6. PubMed ID: 14571352 [Abstract] [Full Text] [Related]
3. Effects of acute cholecystokinin infusion on hemispheric EEG asymmetry and coherence in healthy volunteers. Knott V, Mahoney C, Bradwejn J, Shlik J, Gunnarsson T. Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):179-84. PubMed ID: 12551742 [Abstract] [Full Text] [Related]
4. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls. Koszycki D, Torres S, Swain JE, Bradwejn J. Psychosom Med; 2005 Feb; 67(4):590-5. PubMed ID: 16046372 [Abstract] [Full Text] [Related]
5. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. Maron E, Tõru I, Vasar V, Shlik J. J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907 [Abstract] [Full Text] [Related]
13. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K. Depress Anxiety; 2006 Jun; 23(3):139-44. PubMed ID: 16470820 [Abstract] [Full Text] [Related]
14. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men. Dépôt M, Merani S, Bradwejn J, Mukherjee J, Caillé J, Gutkowska J, Caillé G. J Psychiatry Neurosci; 1998 Nov; 23(5):298-304. PubMed ID: 9846035 [Abstract] [Full Text] [Related]
15. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI. Schunck T, Mathis A, Erb G, Namer IJ, Hode Y, Demazières A, Luthringer R. J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136 [Abstract] [Full Text] [Related]
16. Dose ranging study of the effects of cholecystokinin in healthy volunteers. Bradwejn J, Koszycki D, Bourin M. J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739 [Abstract] [Full Text] [Related]
17. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Koszycki D, Zacharko RM, Le Mellédo JM, Bradwejn J. Depress Anxiety; 1998 Jul; 8(1):1-7. PubMed ID: 9750972 [Abstract] [Full Text] [Related]
18. Brain potential signs of slowed stimulus processing following cholecystokinin in Parkinson's disease. Smolnik R, Fischer S, Hagenah J, Kis B, Born J, Vieregge P. Psychopharmacology (Berl); 2002 Apr; 161(1):70-6. PubMed ID: 11967633 [Abstract] [Full Text] [Related]
19. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Koszycki D, Zacharko RM, Le Melledo JM, Young SN, Bradwejn J. Biol Psychiatry; 1996 Oct 01; 40(7):648-55. PubMed ID: 8886299 [Abstract] [Full Text] [Related]
20. Effect of aging on cholecystokinin-induced panic. Flint AJ, Koszycki D, Vaccarino FJ, Cadieux A, Boulenger JP, Bradwejn J. Am J Psychiatry; 1998 Feb 01; 155(2):283-5. PubMed ID: 9464213 [Abstract] [Full Text] [Related] Page: [Next] [New Search]